• The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030.
• SNGX’s HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL.
• HyBryte(TM) is a novel therapy based on photodynamic therapy, which combines light and a photosensitizer to target and destroy cancer cells.

The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The market for treatments in this space is substantial, as rare diseases collectively affect millions of people worldwide. Among those working tirelessly to fill these gaps is Soligenix (NASDAQ: SNGX), a biopharmaceutical company that is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma, a rare form of cancer that affects the skin.

The global market for rare disease treatments is growing at an impressive rate. According to a report by Grand View Research, the global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030 (https://ibn.fm/ePKDT).

“The presence of a strong product pipeline and their expected launches are expected to drive market growth,” the report stated. “For instance, in October 2024, the FDA announced seven new clinical trial grants for advancement in research on rare disease treatments, which are often overlooked. These new projects include the treatment for cancer, Cushing’s syndrome, lymphatic malformations, inherited eye disease and blood disorders. Increased funding for such research projects fuels the launch of new drugs and treatments for diseases and further boosts the market growth.”

Historically, research into rare diseases has faced several challenges, including limited patient populations, the high cost of clinical trials and the complexity of the diseases themselves. However, there have been notable success stories in recent years that demonstrate the potential for breakthrough treatments in this area.

The success of these treatments highlights the enormous potential for progress in rare disease research. For many years, diseases such as cutaneous T-cell lymphoma (“CTCL”) were considered difficult to treat due to their rarity and the challenges of developing targeted therapies. CTCL is a rare type of cancer that originates in the skin and affects the T-cells, a type of white blood cell. It is difficult to diagnose and treat, especially in its early stages, and most treatments are aimed at managing symptoms rather than providing a definitive cure. However, ongoing research and clinical trials are shedding light on potential therapies that may offer a more effective approach to treating CTCL and other rare diseases.

This is where Soligenix comes in. The company has been making significant strides in developing innovative therapies for rare and hard-to-treat diseases, including early-stage cutaneous T-cell lymphoma. Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL (https://ibn.fm/OB4Vd).

According to the most recent news from the company, HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL. “Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,” the company reported. The study results suggest that the treatment may be highly effective in reducing the symptoms of CTCL, providing much-needed hope for patients with this challenging condition.

HyBryte(TM) is a novel therapy based on photodynamic therapy (“PDT”), which combines light and a photosensitizer to target and destroy cancer cells. PDT has been used in the treatment of various cancers, but Soligenix has taken this approach a step further by developing a proprietary drug formulation that is specifically designed for the treatment of CTCL. The recent study results are encouraging, showing that HyBryte(TM) is not only effective but also well-tolerated by patients, with minimal side effects. This is particularly important for patients with rare diseases, as they often face significant challenges in tolerating conventional treatments.

The positive results from the HyBryte(TM) study are a significant step forward for Soligenix, positioning the company as a leader in the development of treatments for rare and difficult-to-treat diseases. Soligenix has demonstrated a clear commitment to addressing the unmet medical needs of patients with rare diseases, and the success of its ongoing research efforts could lead to the approval of a much-needed therapy for CTCL and other rare cancers. The company’s innovative approach, coupled with the growing market for rare-disease treatments, underscores the importance of continued investment in research and development in this critical area of healthcare.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising high-grade copper exploration targets, strategically located adjacent to Canada’s largest copper mine (Highland Valley Copper).
• Immediate Revenue Generation: Operates British Columbia’s only permitted mill capable of processing third-party gold and silver ore, with current throughput supporting strong, near-term cash flow.
• Diverse Revenue Streams: Revenue growth fueled by commercial milling operations, gold concentrate sales, and active aggregate production — providing self-funded exploration and reducing reliance on capital raises.
• Strategic Location & Infrastructure: Centrally located near major transportation routes and mining services, providing cost advantages and operational efficiencies.
• Proven Leadership Team: Led by a management group with extensive track records in mining operations, project development, and capital markets, driving disciplined growth and long-term value creation.

Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. With a unique dual-pronged model, the company combines solid operational revenues from its wholly-owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows Nicola to fund ongoing development while minimizing equity dilution.

The company’s strategy centers on aligning infrastructure and permitting advantages with mineral-rich geology, positioning it to process its own, as well as third-party high-grade gold and silver mines via partnerships, to advance its own exploration targets. Key agreements with gold producers and concentrating sales contracts provide stable cash flow, making Nicola rare among juniors in its ability to internally support growth. Its solid balance sheet and business acumen have allowed it to take stakes in other near-term gold producers, including a 75% economic stake in Dominion Gold, which commences a bulk sample in 2H 2025.

Nicola is leveraging its platform of permitted infrastructure, strategic project locations, and deep technical expertise to build shareholder value in a low-risk, high-reward framework. The company is headquartered in Vancouver, British Columbia.

Projects

Nicola Mining’s project portfolio includes high-grade copper, silver, and gold assets located in mineral-rich regions of British Columbia. Each project is 100%-owned or majority-controlled, with strong exploration potential and the necessary permits to advance development.

New Craigmont Copper Project

Nicola’s flagship asset, the New Craigmont Project, is a historic producer of over 900 million pounds of copper. Since acquiring 100% ownership in 2015, the company has drilled over 18,000 meters and identified significant skarn-hosted and porphyry-style mineralization. Recent drilling in 2024 confirmed 52.9 meters at 1.03% Cu (Hole NC-24-002), supporting the presence of a large-scale copper system. The project benefits from paved road access, connection to BC Hydro’s grid, and proximity to urban centers.

Treasure Mountain Silver Project

This 100%-owned past-producing mine has a Major Mines permit (M-239) and an NI 43-101 compliant resource estimate. The site includes multiple silver-lead-zinc veins and is permitted to extract up to 60,000 tonnes annually. Nicola is evaluating potential reactivation or joint venture options. Resource estimates include indicated resources of 52,000 tonnes grading 18.1 oz/t Ag, 3.26% Pb, and 3.4% Zn, and inferred resources of 161,000 tonnes grading 22.0 oz/t Ag, 2.48% Pb, and 3.86% Zn.

Dominion Creek Project (Au-Ag)

Nicola holds a 50% land ownership and 75% economic stake in this gold-silver project. Located 43 km from Wells, British Columbia, the site has returned grab samples averaging 61.3 g/t Au and 173.7 g/t Ag. The company has received its final permit and plans to extract a 10,000-tonne bulk sample in 2025, which will be processed at its Merritt Mill facility.

Operations

In addition to its exploration assets, Nicola Mining operates a suite of permitted industrial facilities in British Columbia that generate revenue and support the company’s broader development strategy. These assets form the backbone of Nicola’s self-sustaining business model.

Merritt Mill & Tailings Facility

Nicola owns and operates British Columbia’s only provincially permitted toll mill for gold and silver, a $30 million flotation facility located near Merritt. Gold production began in 2023. The facility is supported by long-term Milling and Profit Share Agreements with companies including Osisko Development Corporation, Blue Lagoon Resources, and Talisker Resources.

Sand & Gravel Pit / Rock Quarry / Ready-Mix Concrete Plant

Nicola also operates a permitted gravel pit (100,000 t/year), rock quarry (1,500 t/day), and is set to launch a ready-mix cement plant in Q2 2025. These operations, run in partnership with local First Nations, generate stable cash flow to support exploration efforts.

Market Opportunity

Nicola Mining is uniquely positioned in southern British Columbia, a jurisdiction recognized for its mining-friendly policies, skilled labor force, and robust infrastructure. The New Craigmont Project is geologically situated within the Guichon Creek Batholith, a region hosting some of Canada’s largest copper mines, including Highland Valley. Exploration data from 2023 and 2024 support the potential presence of both skarn and porphyry systems, increasing the strategic value of Nicola’s holdings.

The company’s other assets, including Treasure Mountain and Dominion Creek, are located in historically productive areas with high-grade mineralization and established access routes. Dominion Creek, in particular, sits atop the Isaac Lake Fault system—identified in British Columbia’s RGS (Regional Geochemical Survey) as a highly anomalous gold-silver corridor. Nicola’s integrated production model enables it to generate revenue while advancing these exploration programs without excessive dilution, providing a distinct advantage in a volatile commodities market.

Leadership Team

Peter Espig, Chief Executive Officer & Director, is a former diamond driller who spearheaded Nicola through a restructuring into its recent growth. He brings over $2 billion in private equity transaction experience, is a pioneer of SPACs, and has held senior positions at Goldman Sachs Japan and Olympus Capital.

Will Whitty, VP of Exploration, brings to the company over 15 years of experience in copper and gold exploration. He previously worked at Freeport-McMoRan and Nevada Gold Mines. He holds a master’s degree from the Mineral Deposit Research Unit (“MDRU”) at the University of British Columbia.

Bill Cawker, Corporate Development, manages investor relations, communications, and corporate governance. He joined Nicola in 2023 and brings extensive small-cap public markets experience, along with a degree in economics from the University of British Columbia.

Sam Wong, Chief Financial Officer, is a CPA with over 18 years of experience in the mining sector. He previously held executive roles at several publicly listed resource companies. He began his career at Deloitte LLP in Vancouver.

For more information, visit the company’s website at www.NicolaMining.com.

NOTE TO INVESTORS: The latest news and updates relating to HUSIF are available in the company’s newsroom at https://ibn.fm/HUSIF

• Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.
• Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors.
• The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors.

Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.

This is where cutting-edge innovations, such as those pioneered by Calidi Biotherapeutics (NYSE American: CLDI), come into play. Calidi Biotherapeutics recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors (https://ibn.fm/bbPdB). This novel platform has demonstrated an impressive ability to successfully deliver therapeutic agents to tumor cells while minimizing damage to surrounding healthy tissues. By targeting tumors more effectively, this approach holds the potential to significantly improve treatment outcomes and reduce side effects.

Progress in cancer research has led to remarkable advancements that have improved survival rates and quality of life for many patients. From the development of targeted therapies and immunotherapies to advancements in precision medicine, these breakthroughs have reshaped the landscape of cancer treatment. Preclinical and clinical trials play a vital role in this progress by testing new drugs, therapies and treatment combinations, ensuring that only the most effective and safest options reach patients.

The journey from concept to clinical application is long and complex, with preclinical studies playing a critical role in determining the safety and efficacy of new therapies. These studies involve rigorous testing in laboratory settings, where researchers evaluate how well a treatment works on cancer cells and assess its safety before moving on to human clinical trials. Calidi’s success in preclinical models is a promising sign that its RTNova platform and tumor-specific virotherapy may achieve statistical efficacy in clinical evaluation, offering a glimpse of hope for future cancer patients.

Preclinical data provides crucial insights into how a therapy interacts with cancer cells, paving the way for carefully designed clinical trials. In the case of Calidi’s RTNova platform, the ability to deliver therapeutic payloads with precision while simultaneously attacking tumors represents a significant leap forward in cancer treatment strategies. This innovative approach could potentially revolutionize how gene therapy is applied to various cancer types, enhancing the immune response and improving treatment outcomes for patients.

As the global burden of cancer continues to rise, the need for groundbreaking therapies becomes even more urgent. Companies such as Calidi Biotherapeutics are leading the charge in developing transformative therapies that have the potential to change the course of cancer treatment. With the company’s ongoing research and deep commitment to scientific excellence, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards
• The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article
• Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future

Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being named a finalist for the prestigious EY Entrepreneur of the Year Awards to providing key insights in a BBC News feature on Irish companies operating internationally and sharing their strategic vision in a wide-ranging interview, NTRB’s voice is increasingly shaping discussions around entrepreneurship, innovation and the future of healthcare.

In a major milestone for his career, Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards (https://ibn.fm/U1Tpb). He has been recognized in the International Category, which honors entrepreneurs whose companies have a significant footprint beyond their home countries.

The EY Entrepreneur of the Year program is considered one of the most prestigious accolades for business leaders worldwide, celebrating individuals who not only demonstrate exceptional business acumen but who also embody vision, leadership and innovation. Being shortlisted in this global category is a significant achievement, placing Sheridan among the elite group of entrepreneurs who are not just excelling in their home markets but are actively shaping industries on a global scale. This recognition serves as a testament to Sheridan’s ability to lead Nutriband into new markets and pioneer technologies that have international significance.

Sheridan’s international perspective and expertise were further validated when he was featured and quoted in a recent BBC News article discussing Irish businesses expanding into the U.S. market (https://ibn.fm/3yRSp). The article examined the shifting landscape for Irish companies as they seek growth opportunities in America, particularly in sectors such as pharmaceuticals, technology and manufacturing.

Sheridan, representing Nutriband as an Irish-founded company operating in the United States, offered valuable insights into the challenges and opportunities of such a transition. He noted that while the American market presents significant potential, success depends on a company’s ability to adapt and innovate within a highly competitive and regulated environment.

“The market is there for Irish companies that are innovative and prepared to scale globally, but you must understand the nuances of operating within the American regulatory and commercial environment,” said Sheridan. His comments, featured prominently among those of other seasoned entrepreneurs and policymakers, reflect Sheridan’s respected status in the international business community and underscore his firsthand understanding of what it takes to succeed on the global stage.

Adding further to NTRB’s growing public profile, Melnik participated in a detailed YouTube market interview where he spoke about Nutriband’s mission, achievements and plans for the future (https://ibn.fm/4bFtl). During the interview, Sheridan outlined the evolution of Nutriband from its early days to its current role as a pioneer in abuse-deterrent transdermal drug delivery technologies. He explained the scientific foundation behind AVERSA(TM), Nutriband’s flagship product designed to deter the abuse of opioid medications through innovative patch technology.

Melnik also emphasized the importance of pairing innovation with regulatory navigation, highlighting the significance of the FDA’s fast-track designation for AVERSA and the company’s commitment to bringing safer medications to the market. Throughout the interview, Serguei conveyed a blend of technical expertise and visionary thinking, showcasing not only a deep understanding of the healthcare challenges facing the world today but also a clear strategic roadmap for addressing them through Nutriband’s technologies.

NTRB demonstrates the qualities that are increasingly making this company a standout name in healthcare. The team’s ability to seamlessly bridge scientific innovation with global business strategy positions them uniquely among today’s new generation of CEOs. Whether driving Nutriband’s growth through regulatory milestones, navigating international expansion or sharing insights with a broader audience, Nutriband consistently exhibits the forward-thinking mindset and leadership required to build sustainable, impactful companies in today’s complex global environment.

As Nutriband continues to advance its mission to improve patient safety through innovative transdermal delivery systems, the board’s influence and leadership are key driving forces behind its success. Their recent recognition and contributions to important industry conversations are not only well-deserved but are also setting new standards for what healthcare entrepreneurship can achieve on a global scale.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals.
• The company is actively pursuing an acquisition-driven expansion strategy to grow its marketing agency network.
• ONAR Labs provides a proprietary technology pipeline, offering additional revenue streams beyond traditional marketing services.
• A strong leadership team with proven track records in business growth, financial management, and technology commercialization positions the company for long-term success.
• ONAR’s focus on middle-market and growth-stage clients aligns with sectors expected to see a sustained rise in marketing spend over the next decade.

ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

• Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
• Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
• CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
• ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well-positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, just recorded the highest market value increase for its portfolio club, S.S. Juve Stabia S.r.l
• The club posted a 36.9% increase since March 15, 2025, an increase from €11.78 million to €16.13 million
• For Brera, this growth demonstrates the swift impact of its ownership, and the club’s growing competitiveness, on and off the pitch

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, just crossed a significant milestone with S.S. Juve Stabia S.r.l. Dubbed “The Second Team of Naples,” Juve Stabia just recorded the highest market value increase in Italy’s Serie B, according to Transfermarkt. This demonstrates Brera’s ownership’s swift impact on the club, pointing to the latter’s growing competitiveness, on and off the pitch.

“This extraordinary growth reflects both the untapped potential of Juve Stabia and Brera’s value-creation strategy in action,” noted Brera’s Executive Chairman, Daniel McClory.

“Our focus on operational alignment, player development, and shareholder governance is already bearing fruit. We’re proud of the progress and even more excited for what lies ahead,” he added (https://ibn.fm/YVaV3).

The club posted a 36.9% increase since March 15, 2025, with the squad’s value increasing from €11.78 million to €16.13 million. As of April 29, Juve Stabia ranked 5th in the Serie B standings. Of the 34 matches played thus far, it secured 50 points. Overall, the club has been lauded for its competitiveness on the pitch and the quality of its matches. This factor has grown its popularity, both in Italy and beyond (https://ibn.fm/YVaV3).

On April 5, the club recorded the season’s highest home attendance, attracting 7,000 fans, just 100 seats shy of a full sell-out given the stadium’s 7,100 capacity (https://ibn.fm/vjuwi). In addition, the club saw international recognition, with its match against Cremonese that was broadcast live in the United States, Canada, and the United Kingdom, reflecting the rising trajectory of the club’s global relevance (https://ibn.fm/8UXqa). The Thursday, May 1 match at home v. Catanzaro will be broadcast live in English for those three countries as well, on Destination Calcio.

Brera initiated the acquisition of S.S. Juve Stabia in December 2024, granting it a controlling stake in the club. The process was to take on three steps, the third of which was closed on Feb. 12, 2025, bringing the company’s current stake up to 38.46%. The Italian Football Federation (“FIGC”) also recently approved the acquisition, a testament to its commitment to transparency and institutional excellence. Its investment in the club also shows its confidence in its potential, both on and off the pitch.

For company information, visit www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• ESGold Corp. is connecting with Canadian and Quebec governments for potential non-dilutive funding to support its Montauban Project.
• The company is targeting near-term gold and silver production while focusing on sustainable mining practices.
• ESGold plans to create 20 to 30 new direct jobs and additional contract employment through exploration activities.
• Investment into clean technology and proprietary mining methods is a key part of the company’s growth strategy.
• ESGold shares offer an affordable way for investors to gain exposure to gold amid historically high commodity prices.

ESGold (CSE: ESAU) (OTCQB: ESAUF) is moving closer to gold and silver production at its Montauban Project in Quebec, with the company now actively exploring funding partnerships with both provincial and federal governments. The focus of these discussions is to secure non-dilutive support that aligns with broader goals of sustainability, innovation, and regional job creation, according to a company press release (https://ibn.fm/cBRI3).

The Montauban Project covers 265 mining claims across 13,116 hectares and is fully permitted for construction. ESGold has begun developing a 500-tonne pilot plant and plans to scale up to a 1,000-tonne commercial facility, with first gold and silver production expected later this year. The company’s collaborative approach with government stakeholders reflects an effort to align with Quebec’s clean industry initiatives and Canada’s economic diversification goals.

Discussions with government entities include potential support for construction, equipment acquisition, and continued technological innovation. These partnerships, if finalized, would provide ESGold with non-dilutive capital—allowing the company to finance key growth initiatives without increasing shareholder dilution.

Job creation is central to the Montauban Project’s anticipated impact. ESGold expects to generate between 20 and 30 new direct jobs during its production phase, while exploration drilling across its land package will drive additional contract employment for drill operators, geologists, and lab technicians. By prioritizing local hiring and contractor use, the company aims to deliver tangible economic benefits to the region.

Environmental stewardship is another pillar of ESGold’s development plan. The company is investing in high-performance equipment and developing proprietary technologies designed to minimize environmental impact and optimize operational efficiency. These measures are intended to position ESGold as a participant in the broader movement toward cleaner, more responsible mining practices.

Exploration work remains an important part of ESGold’s long-term strategy. Expanding the resource base at Montauban through additional drilling could extend the life of the mine and increase production potential. In turn, this could enhance the company’s valuation and further differentiate ESGold from other junior miners seeking to move into production.

Importantly, ESGold offers investors a relatively low-cost entry point into the gold sector at a time when gold prices remain high. Unlike purchasing physical gold, which ties investors directly to current commodity prices, ESGold shares offer exposure to the potential upside of new production at a project that is fully permitted and already under construction. This structure could provide greater return potential if gold prices rise further or if ESGold successfully ramps up production in 2025.

Brad Kitchen, President of ESGold, emphasized that the company’s goal is to create lasting value for both shareholders and the communities where it operates. “By engaging in meaningful collaboration with government stakeholders, we aim to position Montauban as a model of clean resource development and economic revitalization,” Kitchen said.

For more information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Nightfood is driving change through technology-enabled solutions that are reshaping how the hospitality sector operates and connects with guests
• NGTF offers cutting-edge Robotics-as-a-Service (“RaaS”) solutions that address service challenges head-on
• The company is also pursuing strategic hotel acquisitions to serve as real-world showcases for its hospitality tech

The hospitality industry has undergone a major transformation. As travel increases and guest expectations evolve, hoteliers are under more pressure than ever to deliver personalized, seamless and proactive service — all while managing rising costs and operational complexity. This dynamic environment calls for innovation not only to stay competitive but to thrive before smart technology becomes a standard within all hospitality businesses. Nightfood Holdings (OTCQB: NGTF), a forward-thinking holding company, is emerging as a key player driving this change through technology-enabled solutions that are reshaping how the hospitality sector operates in this modernized world.

One of the most pressing challenges in hospitality today is the widening gap between demand for service and available labor. According to the American Hotel & Lodging Association (“AHLA”), more than 80% of hotels are facing staffing shortages, with housekeeping being the most critical area (https://ibn.fm/bKAOE). At the same time, guest expectations have never been higher. Travelers expect real-time responses, personalized experiences and consistent service—whether they’re staying at a five-star resort or a mid-range city hotel. Traditional systems simply can’t keep up.

This is where Nightfood Holdings steps in. Through its wholly owned subsidiary Skytech, NGTF offers cutting-edge Robotics-as-a-Service (“RaaS”) solutions that address these challenges head-on. These innovative solutions aren’t gimmicky tech upgrades — they’re transformative tools that are attacking real world problems, giving businesses and the staff great returns with Skytech’s unique capabilities (https://ibn.fm/CEvaK).

To continue, NGTF’s operating company, Future Hospitality Ventures,  includes service robots and smart automation tools that perform everything from food delivery to front-desk concierge functions (https://ibn.fm/d6Hqp). But it’s the integration of predictive analytics and intuitive robotics that makes these solutions truly powerful. By analyzing guest behavior and leveraging machine learning, these technologies help hotel teams anticipate needs before they arise. For example, if a frequent traveler prefers a certain room temperature or requests extra towels during previous stays, the system can accommodate those preferences without the guest ever having to ask. This shift from reactive to proactive service is more than just a technological advancement, it’s a new hospitality paradigm.

Important to note, NGTF is pursuing strategic hotel acquisitions to serve as real-world showcases for its hospitality tech. A recent $41 million letter of intent to acquire a Victorville, California, property underscores this approach (https://ibn.fm/iEfc7). The company plans to transform this hotel into a flagship model for robotics-enabled hospitality, demonstrating the ROI of automation in real time. These initiatives are designed to accelerate revenue, create cost savings and validate the effectiveness of Nightfood’s RaaS offerings across diverse hospitality environments 

The market potential for this innovation is significant. The global hospitality robotics market is projected to reach $65.4 billion by 2032, driven by increased demand for operational automation and service personalization (https://ibn.fm/LCPZS). As one of the few publicly traded companies uniquely positioned at the intersection of hospitality and AI, NGTF stands to offer a compelling investment opportunity for forward-looking stakeholders.

Nightfood Holdings is clearly not just another tech vendor or service provider — it’s a catalyst for the next era of hospitality. By combining intelligent automation with a human-centric vision, NGTF is helping hotels adapt to modern demands while staying true to the core of hospitality. investors seeking a foothold in the future of this evolving industry before it’s too late, Nightfood Holdings is truly a win-win scenario.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• “Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute.
• CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors.
• “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO.

Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role of research in combating cancer.

The significance of research in cancer treatment cannot be overstated. Through dedicated efforts, scientists have deepened our understanding of cancer biology, leading to the development of targeted therapies that attack specific molecular abnormalities in cancer cells. This precision medicine approach has revolutionized treatment protocols, resulting in therapies that are more effective and less harmful to healthy tissues.

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” states the National Cancer Institute (https://ibn.fm/LO44e). “Treatment advances, in combination with innovative diagnostic tools, are leading to therapies that are increasingly tailored to the cancer’s unique traits.”

Clinical trials are integral to translating research discoveries into clinical applications. These trials rigorously evaluate the safety and efficacy of new treatments, ensuring that only those with proven benefits reach patients. Participation in clinical trials not only provides patients with access to cutting-edge therapies but also contributes to the collective understanding of cancer treatment, paving the way for future innovations.

Calidi Biotherapeutics, a clinical-stage biotechnology company, exemplifies the fruits of rigorous research in its recent announcement (https://ibn.fm/F71fk). The company is reporting promising preclinical results for its systemic RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. Additionally, Calidi’s tumor-specific virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation.

“Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown that our systemic platform can act also as a viral vector to express therapeutic genes in target tumors, which will maximize the potential of the designed treatment. With this breakthrough, we can use our platform to develop multiple assets for various indications, opening the door for potential partnership opportunities.”

The RTNova platform addresses significant challenges in treating advanced-stage metastatic cancers, such as lung cancer, where direct tumor injection is not feasible. Calidi has engineered a novel vaccinia virus strain enveloped with a human cell membrane, known as an extracellular enveloped virus (“EEV”). This design provides protection in the bloodstream while targeting distant tumors. Upon reaching the tumor, the virotherapy selectively replicates and destroys tumor cells, inducing an immune response that trains the immune system to recognize and target future cancer cells. Furthermore, the platform’s ability to target distant tumors allows it to act as a viral vector, delivering specific gene therapies directly to tumor sites.

Research serves as the backbone of progress in cancer treatment, leading to the development of innovative therapies that improve patient outcomes. Calidi Biotherapeutics’ recent preclinical success with the RTNova platform exemplifies how dedicated research can yield promising new treatment avenues, reinforcing the vital importance of continued investment in cancer research.

Calidi Biotherapeutics is committed to advancing the RTNova platform into clinical development, aiming to provide a novel therapeutic option for patients with metastatic cancers. The company’s mission centers on leveraging cutting-edge research to develop targeted immunotherapies that address unmet medical needs in oncology. By focusing on innovative approaches like the RTNova platform, Calidi strives to transform the landscape of cancer treatment, offering new hope to patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• Report notes that the increasing pace of transactions serves as an encouraging sign for the hospitality industry
• Nightfood Holdings has closed on two acquisitions this month alone
• Company is “building a powerful ecosystem designed to lead the future of hotel automation,” says chair

Strategic acquisitions are a cornerstone for companies aiming to scale and diversify, particularly in the hospitality sector, where consumer preferences and technological advancements rapidly evolve. In this dynamic environment, Nightfood Holdings (OTCQB: NGTF) has demonstrated its commitment to savvy acquisitions in the past six months, positioning itself to capitalize on emerging robotic trends and broaden its market presence.

“The year 2024 marked a significant period of strategic consolidation within the hotel management industry, reflecting a deeper trend beyond mere financial transactions,” stated a recent ReportLinker article (https://ibn.fm/TZpQk). “These mergers and acquisitions (“M&A”) signal a substantial shift in the way hotel management companies are positioning themselves in an ever-evolving market landscape.”

“This increasing pace of transactions serves as an encouraging sign for the hospitality industry, suggesting not only a recovery from any past market slowdowns but also an optimistic outlook for the future,” the article continued. “The strategic nature of these mergers and acquisitions, focusing on scalability, market penetration and operational synergies, highlights a proactive approach to navigating the challenges and opportunities of the hospitality market.”

Nightfood Holdings’ recent acquisitions reflect this strategic approach. In September 2024, Nightfood completed the acquisition of CarryoutSupplies.com, a leading wholesaler and distributor of custom takeout packaging for the food-service industry (https://ibn.fm/N3UA3). This strategic all-stock acquisition expanded Nightfood’s product offerings and customer base, enhancing operational efficiencies and opening new avenues for cross-promotion within its subsidiaries.

“Acquiring Carryout Supplies is a major step forward in our strategy to transform hospitality operations,” said Jamie Steigerwald, chair of Nightfood Holdings. “Combining their industry-leading packaging capabilities with our advanced automation technology enables us to offer more efficient, scalable solutions that directly address cost, labor, and operational challenges in the sector.”

The company has closed on two additional acquisitions this month. On April 1, the company announced the successful acquisition of Skytech Automated Solutions Inc., a recognized expert in artificial intelligence (“AI”)-driven service technologies for the hotel industry (https://ibn.fm/joUNP). This acquisition enhances Nightfood Holdings’ Robots-as-a-service (“RaaS”) capabilities and accelerates market penetration across the hotel sector – with robotics being an inevitable evolution that forward-thinking businesses will need to embrace to lead in the future.

“Closing the Skytech acquisition represents a transformative leap forward for Nightfood,” said Steigerwald. “This strengthens our ability to scale automation across the hospitality industry-addressing key operational pain points such as labor shortages and rising costs. Together with the Carryout Supplies acquisition, we’re building a powerful ecosystem designed to lead the future of hotel automation.”

In addition, Nightfood has signed a letter of intent (“LOI”) to acquire the assets of Victorville Treasure Holdings LLC, owner and operator of a 155-room Holiday Inn(R) in Victorville, California (https://ibn.fm/BrIyb). This acquisition represents the company’s plan to become a leader in hotel ownership and management; Nightfood Holdings has developed more than 50 properties and manages more than 130 hotels.

The Victorville property is undergoing a major renovation, including the addition of a new state-of-the-art fitness center, to qualify for the Courtyard by Marriott(R) rebranding. Following the acquisition, Nightfood plans to continue developing the site as a model property and proof-of-concept for its integrated RaaS platform and hospitality asset management approach-one of many more to come.

“This transaction marks another milestone in Nightfood’s aggressive acquisition strategy, further expanding its footprint in hospitality real estate and smart-service automation,” the company observed. “The Victorville property utilizes Skytech’s robotic technologies to reduce operating costs and improve profitability.

Through these strategic acquisitions, Nightfood Holdings is not only expanding its operational capabilities but also reinforcing its position as a leader in the transition to a more modern and efficient hospitality sector as well as hotel management. By identifying and integrating complementary businesses, the company is poised to enhance its market position and deliver value to stakeholders.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF